Search Results for “immune” – Page 91 – media

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients

Merck, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
- Source: Merck
- 547
- September 25, 2017
adenocarcinoma anti-PD-1 GEJ keytruda New Approvals
Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 823
- September 15, 2017
cell immune Series therapy
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell
FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
- Source: news.open-medical
- 581
- September 6, 2017
BPDCN CAR–T Clinical Trials Company Insight CRS
Merck sees promise in Macrophage Pharma

Merck Ventures has become the latest group to invest in Macrophage Pharma and take a position on the UK biotech’s board of directors.
- Source: pharmatimes
- 633
- August 25, 2017
Clinical Market Views Merck
New flu vaccine approved for UK use

The adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older has been cleared by the Medicines and Healthcare products Regulatory Agency.
- Source: pharmatimes
- 673
- August 23, 2017
influenza New Approvals trivalent vaccine
Cynvenio Biosystems initiates breast cancer monitoring study in US

Cynvenio Biosystems has initiated a clinical study to evaluate its LiquidBiopsy ClearID test in combination with NK Score natural killer cell activity to monitor breast cancer patients in the US.
- Source: medicaldevice-network
- 560
- August 22, 2017
breast cancer Clinical Researches
AstraZeneca announces new mRNA collaboration

A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
- Source: pharmatimes
- 803
- August 22, 2017
asthma chronic collaboration Company Insight mRNA therapy
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 512
- August 4, 2017
Company Insight

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.